◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HomeAll stocks0-9 › 2186

Luye Pharma Group Ltd. (2186) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Drug Manufacturers - Specialty & Generic · DATA UPDATED 2026-08-11

Luye Pharma Group Ltd. (2186) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Yantai, China with about 5,221 employees. Its market capitalization is roughly CNY 8 billion. In the fiscal year ended 2025-12-31, 2186 reported CNY 6.3B in revenue and CNY 619M in net income.

Luye Pharma Group Ltd., together with its subsidiaries, develops, produces, markets, and sells pharmaceutical products in the People's Republic of China, the United States, Europe, and internationally.

Interactive charts & full statements →

2186 Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-312022-12-312021-12-31
Total RevenueCNY 6.3BCNY 6.1BCNY 6.1BCNY 6.0B
Gross ProfitCNY 4.2BCNY 4.0BCNY 4.2BCNY 4.1B
Operating Income (EBIT)CNY 1.3BCNY 1.3BCNY 1.0BCNY 954M
Net IncomeCNY 619MCNY 472MCNY 533MCNY 605M

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

2186 Free Cash Flow History

2186 Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-312022-12-312021-12-31
Total AssetsCNY 32.8BCNY 29.6BCNY 25.5BCNY 24.2B
Total LiabilitiesCNY 14.5BCNY 13.9BCNY 12.0BCNY 13.2B

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 2186 viewer.

Other Companies in Drug Manufacturers - Specialty & Generic

← 2185All “0-9” companies2187 →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.